This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 07:40, 19 January 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:40, 19 January 2011 by Pashihiko (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | nil |
| Metabolism | nil |
| Elimination half-life | n/a |
| Excretion | faecal 100% |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | m where a+b:c = 9:1 |
| Molar mass | variable |
Sevelamer (rINN) (Template:Pron-en, /sɛˈvɛləmɪər/) is a phosphate binding drug used to prevent hyperphosphatemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade names Renagel and Renvela (carbonate formulation).
Chemistry and pharmacology
Sevelamer is a copolymer of 2-(chloromethyl)oxirane (epichlorohydrin) and prop-2-en-1-amine. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphorus molecules through ionic and hydrogen bonding.
Clinical use
Indications
Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic renal failure on hemodialysis.
Contraindications
Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.
Adverse effects
Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.
Other effects
Sevelamer can significantly reduce serum uric acid. This reduction has no known detrimental effect and several beneficial effects, including reducing hyperuricemia, uric acid nephrolithiasis, and gout.
External links
References
- Garg JP, Chasan-Taber S, Blair A; et al. (2005). "Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial". Arthritis and rheumatism. 52 (1): 290–5. doi:10.1002/art.20781. PMID 15641045.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
| Drugs for treatment of hyperkalemia and hyperphosphatemia (V03AE) | |
|---|---|
| Potassium binders | |
| Phosphate binders | |